Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chongqing Jianqiao Sues HolleyPharm Again For Patent Infringement

This article was originally published in PharmAsia News

Executive Summary

Chongqing Jianqiao Pharmaceutical Development has again sued Holley Pharmaceuticals, alleging that the latter's Duo-Cotecxin (dihyhroartermisinin piperaquine) tablets infringe on its patented compound for piperaquine tablets. Chongqing Jianqiao demands that HolleyPharm stop production and sale of the product, pay RMB 1 for economic losses, as well as issue a public apology and pay for court expenses. HolleyPharm claims thatDuo-Cotecxin's components are totally different from those of Chongqing Jianqiao's piperaquine tablets and it will be fighting the suit. Meanwhile, HolleyPharm has appealed its previous patent infringement case (PharmAsia News, Jul. 28, 2008). Analysts observe that an unfavourable ruling will negatively impact the firm as it will have to stop producing and selling Duo-Cotecxin locally if it loses the two cases. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067171

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel